arrow
T

Tadakazu Hisamatsu

kyorin university school of medicine
H指数:60
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)

奥法木单抗(carotegrast methyl)口服α4整合素拮抗剂治疗活动性溃疡性结肠炎的有效性、安全性和临床结局:一项多中心观察性研究(CANAL研究)

2026-09-280
OAAI
Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials

古塞库单抗在东亚中度至重度活动性克罗恩病患者中的疗效与安全性:GALAXI 2和GALAXI 3三期试验的亚组分析

2026-05-010
PRE
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis

先进疗法在中重度克罗恩病成年患者维持治疗中的疗效和安全性比较: 系统文献回顾和网络荟萃分析

2026-01-190
OAAI
Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2)

奥贝非齐莫德在患有中度至重度活动性溃疡性结肠炎患者中的疗效与安全性:来自两项为期8周的诱导治疗期3期、随机、双盲、安慰剂对照试验(ABTECT-1和2)的结果

2025-12-010
PRE
Questionnaire Survey on the Current Status of Advanced Therapy for Inflammatory Bowel Disease in Asia

亚洲地区炎症性肠病晚期治疗现状的问卷调查

2025-11-010
PRE
Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a post hoc analysis of safety and effectiveness in older (≥ 65 years) and younger (<65 years) patients

日本溃疡性结肠炎患者中托法替布上市后监测:一项针对老年(≥65岁)和年轻(<65岁)患者安全性与有效性的事后分析

2025-11-010
PRE
Guselkumab Pharmacokinetics and Exposure-Response Relationships Are Consistent Following Intravenous vs Subcutaneous Induction in Participants With Crohn's Disease

Guselkumab的药代动力学和暴露-反应关系在克罗恩病患者中,静脉诱导与皮下诱导后保持一致。

2025-10-010
PRE
Maintenance of Endoscopic and Histologic Efficacy With Guselkumab for Ulcerative Colitis at Week 92 of the QUASAR Long-Term Extension Study

在QUASAR长期扩展研究中,Guselkumab对溃疡性结肠炎患者内镜和组织学疗效的维持至第92周。

2025-10-010
PRE
A Multicenter Observational Study for the Establishment of Novel Severity Criteria Including Endoscopic Evaluation for Intestinal Behçet's Disease

一项多中心观察性研究,旨在建立包含内镜评估的新型肠道白塞病严重程度标准

2025-09-270
OAAI
Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study

日本早期炎症性肠病患者中脊柱关节炎的患病率、特征及筛查:一项前瞻性多学科研究

2025-09-180
PRE
Vaginal Lactobacillus crispatus in early pregnancy associates with favorable gestational outcomes in a Japanese maternal-neonatal microbiome cohort

Oguri, N.; Kobayashi, C.; Ozawa, Y.; Kimura, T.; Nishinarita, Y.; Wada, H.; Nemoto, N.; Narita, M.; Tanigaki, S.; Hanawa, T.; et al. 早孕期间阴道乳杆菌 crispatus 与日本母婴微生物组队列中良好的妊娠结局相关。Nat. Commun. 2025, 16, 8032. [Google Scholar] [CrossRef] [PubMed]

2025-09-100
OAAI
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials

古塞库单抗静脉诱导及皮下维持疗法治疗克罗恩病的有效性与安全性(GALAXI-2和GALAXI-3):两项III期、随机、安慰剂及活性对照、双盲、三模拟临床试验的48周结果

2025-07-170
PRE